Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 99
Healthy volunteers: no

Brief summary:
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Detailed description:

Arms:
arm 1: BI1744 Low Dose once daily arm 2: BI 1744 Med Dose once daily arm 3: Placebo once daily arm 4: Foradil 12 mcg twice daily

Interventions: intervention 1: BI 1744 intervention 2: bi1744 intervention 3: Placebo intervention 4: Foradil
Intervention descriptions: intervention 1: BI1744 Respimat Med Dose Once Daily intervention 2: 1744 low dose intervention 3: Placebo Respimat and Foradil Placebo intervention 4: Foradil 12 mcg twice daily and Placebo Respimat

Protocol document: